Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease

Pharmacogenetics

Volumn 12, Issue 7, 2002, Pages 529-534

  Furuno, Taku ^a   Landi, Maria Teresa ^a   Ceroni, Mauro ^a   Caporaso, Neil ^a   Bernucci, Ilaria ^a   Nappi, Giuseppe ^a   Martignoni, Emilia ^a   Schaeffeler, Elke ^a   Eichelbaum, Michel ^a   Schwab, Matthias ^a   Zanger, Ulrich M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

ABC transporters; Genetic polymorphism; Morbus parkinson; Multi drug resistance gene; P glycoprotein; Pharmacogenetics

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; XENOBIOTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG UPTAKE; EXON; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGE OF ONSET; BLOOD-BRAIN BARRIER; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENE EXPRESSION REGULATION; GENES, MDR; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 18644367631     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200210000-00004     Document Type: Article

References (34)

1. Ben-Shlomo Y, Sieradzan K. Idiopathic Parkinson's disease: epidemiology, diagnosis and management. Br J Gen Pract 1995; 45:261-268.
2. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
3. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-608.
4. Maimone D, Dominici R, Grimaldi LM. Pharmacogenomics of neurode-generative diseases. Eur J Pharmacol 2001; 413:11-29.
5. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:979-980.
6. Koller W, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, et al. Environmental risk factors in Parkinson's disease. Neurology 1990; 40:1218-1221.
7. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992; 42:1328-1335.
8. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3:1301-1306.
9. Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Adv Neurol 1996; 69:61-72.
10. Checkoway H, Farin FM, Costa-Mallen P, Kirchner SC, Costa LG. Genetic polymorphisms in Parkinson's disease. Neurotoxicology 1998; 19:635-643.
11. Christensen PM, Gotzsche PC, Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics 1998; 8:473-479.
12. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 1998; 8:227-238.
13. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55:533-538.
14. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31:469-497.
15. Le Couteur DG, Davis MW, Webb M, Board PG. P-glycoprotein, multidrug-resistance-associated protein and Parkinson's disease. Eur Neurol 2001; 45:289-290.
16. Fromm MF, Eichelbaum M. The pharmacogenomics of human P-glycoprotein. In: Licinio J, Wong ML, eds. Pharmacogenomics: The search for individualized therapies. Wiley-VCH, Weinheim 2002, pp. 159-178.
17. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-7738.
18. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86:695-698.
19. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse MDR1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77:491-502.
20. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-2524.
21. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001; 11:727-733.
22. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289-294.
23. Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91:1749-1756.
24. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
25. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
26. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137-1143.
27. Siegsmund M, Brinkmann U, Schaeffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1 C3435T polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13:1847-1854.
28. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11:293-298.
29. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
30. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184.
31. Staal RG, Yang JM, Hait WN, Sonsalla PK. Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 2001; 910:116-125.
32. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11:217-221.
33. Schäffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Increased frequency of the P-glycoprotein high-expression genotype C3435T of the MDR1 polymorphism in Africans. Lancet 2001; 358:383-384.
34. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.